Slate Medicines to merge with Fulcrum Therapeutics and raise $245 million to advance migraine pipeline

The reverse-merger transaction gives privately held Slate a Nasdaq listing and additional capital to advance its anti-PACAP migraine portfolio, led by clinical-stage monoclonal antibody SLTE-1009.

Slate Medicines and Fulcrum Therapeutics have agreed to merge in an all-stock transaction that will take Slate public through Fulcrum’s Nasdaq listing, alongside approximately $245 million in committed private financing to support the combined company.

The transaction gives Slate additional capital and public-market access to advance its migraine-focused pipeline, including lead anti-PACAP/VIP monoclonal antibody SLTE-1009, while Fulcrum shareholders are expected to receive a special cash dividend and retain a minority interest in the combined business.

Field	Content
Alert Type	Deal
Companies	Slate Medicines; Fulcrum Therapeutics
Deal Type	All-stock merger / reverse merger with concurrent private financing
Asset or Company	Slate Medicines and its migraine and headache-disorder pipeline, led by SLTE-1009
Therapy Area(s)	Neurology; Migraine; Headache disorders
Technology or Modality	Monoclonal antibodies targeting PACAP/VIP signalling
Deal Value	The transaction is accompanied by approximately $245 million in committed private financing from new and existing investors. This financing represents capital for the combined company rather than consideration paid to acquire Fulcrum. Fulcrum shareholders are also expected to receive a pre-closing special cash dividend, subject to the transaction terms and Fulcrum’s available cash at closing.
Development Stage	Clinical stage; SLTE-1009 is in Phase I development
Geography	United States
What Happened	Slate Medicines and Nasdaq-listed Fulcrum Therapeutics have entered a definitive agreement to combine in an all-stock merger. Following completion, the combined business will operate under the Slate Medicines name and focus on developing therapies for migraine and other headache disorders. The transaction is accompanied by approximately $245 million in committed private financing, while existing Fulcrum shareholders are expected to receive a pre-closing special cash dividend and retain a minority ownership position in the combined company. The merger follows Fulcrum’s June 2026 decision to discontinue development of sickle cell disease candidate pociredir and begin a strategic review after FDA feedback left the company without what it considered a viable regulatory path for the programme.
Why It Matters	The transaction provides Slate with a route to the public markets and additional financing as it advances a differentiated approach to migraine prevention. Its lead candidate, SLTE-1009, targets PACAP/VIP signalling, a mechanism distinct from the CGRP pathway targeted by several established migraine therapies, and has been designed with half-life extension to support subcutaneous administration. (Slate Medicines)
Supporting Context	Slate launched in February 2026 with a $130 million Series A financing and SLTE-1009, which it licensed from DartsBio Pharmaceuticals. The company is developing the antibody for migraine prevention and other headache disorders, particularly with the aim of providing another mechanistic approach for patients who have an inadequate response to existing standards of care. (Slate Medicines)
Strategic Rationale	Slate gains Fulcrum’s Nasdaq listing and access to additional capital without pursuing a conventional IPO, while Fulcrum provides shareholders with a route to realise much of its remaining cash through the planned special dividend while retaining an interest in Slate’s pipeline. Fulcrum entered its strategic review after discontinuing pociredir and subsequently reduced its workforce by approximately 85% to preserve capital.
Potential Impact	The combined financing is intended to support clinical development of SLTE-1009 and Slate’s broader headache-disorder pipeline. Whether the transaction establishes a clinically differentiated migraine franchise will depend on results from SLTE-1009 and subsequent development programmes.
Key Takeaway	The Fulcrum merger gives Slate a Nasdaq-listed vehicle and substantial additional financing to move its anti-PACAP migraine strategy through clinical development.
What to Watch	Completion of the merger and financing, the final value of Fulcrum’s special cash dividend and clinical progress for SLTE-1009, including emerging Phase I data and subsequent migraine efficacy studies.
Primary Source	Fulcrum Therapeutics and Slate Medicines transaction announcement / SEC transaction filings
Relevant Date	17 August 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com